Nanoparticles for the delivery of zoledronic acid to prostate cancer cells: A comparative analysis through time lapse video-microscopy technique

Schiraldi, Chiara; Zappavigna, Silvia; Agostino, Antonella D'; Porto, Stefania; Gaito, Ornella; Lusa, Sara; Lamberti, Monica; Rosa, Mario De; Rosa, Giuseppe De; Caraglia, Michele

doi:10.4161/15384047.2014.955989

Cited by 14 publications

(21 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[7][8][9][10] In fact, we found that stealth Lipo-ZOL induced a significant tumor growth inhibition in different cancer models such as prostate cancer or multiple myeloma compared to free ZOL and improved ZOL pharmacokinetics. [7][8][9][10] In particular, LIPOs showed the highest cytotoxicity compared to free ZOL and NPs on prostate adenocarcinoma cells, as evaluated by time-lapse video microscopy. 10 Moreover, we previously demonstrated that Lipo-ZOL was able to reach active concentrations in CNS.…”

Section: Introductionmentioning

confidence: 81%

“…[7][8][9][10] In particular, LIPOs showed the highest cytotoxicity compared to free ZOL and NPs on prostate adenocarcinoma cells, as evaluated by time-lapse video microscopy. 10 Moreover, we previously demonstrated that Lipo-ZOL was able to reach active concentrations in CNS. When BBB permeability was altered such as in pathological states or chronic neuropathic pain, Lipo-ZOL was able to cross BBB and deliver ZOL in the brain or spinal cord by reducing neuropathic pain.…”

Section: Introductionmentioning

confidence: 99%

“…5,6 Nanotechnologies can help to overcome the limitations of ZOL pharmaco-distribution. [7][8][9][10][11] First generation liposomes have already been used to improve the pharmaco-distribution of aminobisphosphonates but the recognition and interaction with the immune system made these agents not suitable for use in anticancer therapy. 12,13 On the other hand, stealth liposomes (pegylated liposomes or second-generation liposomes) are able to evade the immune system and represent a new potential therapeutic agent.…”

Section: Introductionmentioning

confidence: 99%

“…7 Previously, we developed stealth liposomes encapsulating ZOL (Lipo-ZOL) and self-assembling PEGylated nanoparticles (NPs) consisting of calcium/phosphate NPs and cationic liposomes encapsulating ZOL. [7][8][9][10] Both the developed delivery systems showed promising anticancer activity in vitro and in vivo. [7][8][9][10] In fact, we found that stealth Lipo-ZOL induced a significant tumor growth inhibition in different cancer models such as prostate cancer or multiple myeloma compared to free ZOL and improved ZOL pharmacokinetics.…”

Section: Introductionmentioning

confidence: 99%

“…[7][8][9][10] Both the developed delivery systems showed promising anticancer activity in vitro and in vivo. [7][8][9][10] In fact, we found that stealth Lipo-ZOL induced a significant tumor growth inhibition in different cancer models such as prostate cancer or multiple myeloma compared to free ZOL and improved ZOL pharmacokinetics. [7][8][9][10] In particular, LIPOs showed the highest cytotoxicity compared to free ZOL and NPs on prostate adenocarcinoma cells, as evaluated by time-lapse video microscopy.…”

Section: Introductionmentioning

confidence: 99%

See 4 more Smart Citations

Stealth liposomes for the delivery of zoledronic acid into tumors enhance the anticancer activity of the drug

et al. 2017

Self Cite

View full text Add to dashboard Cite

Zoledronic acid (ZOL) is a third generation aminobisphosphonate, commonly used for the treatment of bone metastases. Several studies have shown a direct in vitro antitumor activity of ZOL but a clear evidence of clinical activity is still lacking. Unfortunately, the use of ZOL as an anticancer agent in extraskeletal tissues is limited probably because it is rapidly removed from the blood and tends to accumulate in the bone. On these bases, we developed stealth liposomes encapsulating ZOL (Lipo-ZOL) to improve the pharmacokinetic profile of the drug. Compared to free ZOL, Lipo-ZOL induced a stronger inhibition of growth in two different cancer cell lines H460 and CG5. Moreover, Lipo-ZOL also significantly caused a larger inhibition of tumor growth and increased the overall survival in murine models of human lung and breast cancer, in comparison with free ZOL. These results suggest the use of Lipo-ZOL as a potential anticancer agent in patients with neoplastic disease.

show abstract

Section: Introductionmentioning

confidence: 81%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Stealth liposomes for the delivery of zoledronic acid into tumors enhance the anticancer activity of the drug

et al. 2017

Self Cite

View full text Add to dashboard Cite

show abstract

Zoledronic acid renders human M1 and M2 macrophages susceptible to Vδ2+ γδ T cell cytotoxicity in a perforin-dependent manner

Fowler

Copier

Dalgleish

et al. 2017

Cancer Immunol Immunother

View full text Add to dashboard Cite

Vδ2+ T cells are a subpopulation of γδ T cells in humans that are cytotoxic towards cells which accumulate isopentenyl pyrophosphate. The nitrogen-containing bisphosphonate, zoledronic acid (ZA), can induce tumour cell lines to accumulate isopentenyl pyrophosphate, thus rendering them more susceptible to Vδ2+ T cell cytotoxicity. However, little is known about whether ZA renders other, non-malignant cell types susceptible. In this study we focussed on macrophages (Mϕs), as these cells have been shown to take up ZA. We differentiated peripheral blood monocytes from healthy donors into Mϕs and then treated them with IFN-γ or IL-4 to generate M1 and M2 Mϕs, respectively. We characterised these Mϕs based on their phenotype and cytokine production and then tested whether ZA rendered them susceptible to Vδ2+ T cell cytotoxicity. Consistent with the literature, IFN-γ-treated Mϕs expressed higher levels of the M1 markers CD64 and IL-12p70, whereas IL-4-treated Mϕs expressed higher levels of the M2 markers CD206 and chemokine (C–C motif) ligand 18. When treated with ZA, both M1 and M2 Mϕs became susceptible to Vδ2+ T cell cytotoxicity. Vδ2+ T cells expressed perforin and degranulated in response to ZA-treated Mϕs as shown by mobilisation of CD107a and CD107b to the cell surface. Furthermore, cytotoxicity towards ZA-treated Mϕs was sensitive—at least in part—to the perforin inhibitor concanamycin A. These findings suggest that ZA can render M1 and M2 Mϕs susceptible to Vδ2+ T cell cytotoxicity in a perforin-dependent manner, which has important implications regarding the use of ZA in cancer immunotherapy.Electronic supplementary materialThe online version of this article (doi:10.1007/s00262-017-2011-1) contains supplementary material, which is available to authorized users.

show abstract

Microfluidic synthesis of zoledronic acid loaded chitosan nanoparticles used for osteogenic differentiation of mesenchymal cells

Khayati

Manjili

Soleimani

et al. 2023

International Journal of Biological Macromolecules

View full text Add to dashboard Cite

Nanoparticles for the delivery of zoledronic acid to prostate cancer cells: A comparative analysis through time lapse video-microscopy technique

Cited by 14 publications

References 22 publications

Stealth liposomes for the delivery of zoledronic acid into tumors enhance the anticancer activity of the drug

Stealth liposomes for the delivery of zoledronic acid into tumors enhance the anticancer activity of the drug

Zoledronic acid renders human M1 and M2 macrophages susceptible to Vδ2+ γδ T cell cytotoxicity in a perforin-dependent manner

Microfluidic synthesis of zoledronic acid loaded chitosan nanoparticles used for osteogenic differentiation of mesenchymal cells

Contact Info

Product

Resources

About